Sunovion completed the acquisition of Cynapsus Therapeutics on October 21, 2016. The announcement can be accessed here
. Visit www.sedar.com
for Cynapsus historic public disclosure documents.
Sunovion specializes in improving lives of patients
Sunovion science revolves around our patients. Rethinking the way medicines are engineered. With a specialized focus on two treatment areas.
Central Nervous System (CNS) disorders can affect people at almost any stage of life. This is why there's a real and urgent need for more treatment options. See what we're working on.
More and more Americans are living with respiratory diseases—among them, asthma, allergies and
chronic obstructive pulmonary disease (COPD). Find out what we're doing to help.